Investing in solid dividend stocks can help navigate the uncertain economic environment we face. Regular payouts can help ...

Amgen (AMGN) is eyeing the obesity drug race, currently dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with its two late-stage weight-loss drug trials. Citi Research managing director Geoff ...

Amgen Inc.'s healthy commercial product portfolio and pipeline position the company well for long-term value creation. Read ...

“Amgen’s takeaway is simple yet profound: The current system is working, and innovation is benefiting actual patients.” The ongoing policy debate about pharmaceutical and biologic patents has been ...

The Dow Jones Industrial Average is climbing Friday morning with shares of Apple and Amgen leading the way for the price-weighted average. Supported by world-class markets data from Dow Jones and ...

Over the last four years, weight-loss drugs that dampen down appetite and promote satiety have revolutionised obesity medicine. They are currently being taken by 1.5 million peopl ...

Over the last four years, weight-loss drugs that dampen down appetite and promote satiety have revolutionised obesity medicine. They are currently being taken by 1.5 million people in the UK and have ...

Amgen, a Thousand Oaks-based biotechnology giant, plans to invest $600 million in a center for science and innovation at its global headquarters. Construction on the advanced automation center where ...

Amgen's new research campus will begin construction this month. (Rendering c/o Amgen) Thousand Oaks-based biotech giant Amgen Inc. announced this month that it plans to invest more than $600 million ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...